Merck's MK-2206 graduates from I-SPY 2

QuantumLeap Healthcare Collaborative said MK-2206 from Merck & Co. Inc. (NYSE:MRK) graduated from the adaptive Phase II I-SPY 2 trial to treat patients with hormone receptor (HR)-negative, HER2-positive, and HR-negative/HER2-positive breast cancer.

I-SPY 2 is designed to test compounds in up to eight different biomarker-defined subgroups of patients with neoadjuvant breast cancer. The program uses Bayesian statistics to predict specific groups in which a compound has at least an 85% chance of success in a Phase III trial. Once a compound is deemed ready for Phase III, it "graduates" from I-SPY 2, making space for new Phase II candidates. ...